Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

U.S. development phase success rates for drugs with and without biomarkers 2006-2015

Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2006 and 2015

by Statista Research Department, last edited May 25, 2016
U.S. development phase success rates for drugs with and without biomarkers 2006-2015 This statistic shows the probability of success for new drugs with and without biomarkers in the U.S. through the various stages of development, in the period from January 1, 2006 to December 31, 2015. It was found that while the probability that a new drug without biomarkers makes it from Phase I to approval was only 8.4 percent, those with selection biomarkers had a probability of success of 25.9 percent.
Show more

Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2006 and 2015

Without biomarkersWith biomarkers
---
---
---
---
---
Without biomarkersWith biomarkers
---
---
---
---
---
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Download Settings Share
Download started
Please be patient - this may take a moment
by Statista Research Department, last edited May 25, 2016
This statistic shows the probability of success for new drugs with and without biomarkers in the U.S. through the various stages of development, in the period from January 1, 2006 to December 31, 2015. It was found that while the probability that a new drug without biomarkers makes it from Phase I to approval was only 8.4 percent, those with selection biomarkers had a probability of success of 25.9 percent.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Personalized medicine
Personalized medicine

All Information
in one Presentation

Personalized medicine

Everything On "Personalized medicine" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Other Reports & Dossiers
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Clinical trials"
  • R&D overview
  • Top R&D companies
  • Clinical studies
  • Participation
  • Costs and market
  • Success rates
The most important statistics
  • Approvals, launches, setbacks
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.